Allan Nixon

Chembio Diagnostics Q1 Revenues Climb 26 Percent on Government Grant Income

Quidel Q1 Revenues More Than Double but Miss Expectations

Natera Q1 Revenues Grow 62 Percent

T2 Biosystems Q1 Revenues Nearly Triple

Fluidigm Q1 Revenues Grow 19 Percent

Accelerate Diagnostics Q1 Revenues Climb 9 Percent, Misses Analyst Estimates